SCIN

Across TCGA pan-cancer cohorts, SCIN Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated SCIN data layer compared with 24 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher SCIN Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SCIN expression acts as an unfavorable survival marker, although some lineages such as UCEC and STAD show a favorable association.

BLCA, UCEC, and SKCM are the cancer types where SCIN Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	III,IV	0.133	0.684	<.001	18	view →
UCEC	DFS	Median	II,III,IV	0.945	0.712	.020	16	view →
SKCM	OS	Median	IV	0.415	0.861	.014	14	view →
ESCA	DFS	Median	II,III,IV	0.190	0.525	.032	9	view →
PRAD	DFS	Median	All	0.617	0.886	.024	6	view →
SCLC	DFS	Median	All	0.210	0.503	.048	3	view →
STAD	DFS	Median	III,IV	1.000	0.324	.043	3	view →
COAD	DFS	Median	All	0.207	0.570	.035	1	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

SCIN–BLCA (OS)

Open the BLCA breakdown →